Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
FAIL · Does not pass the screen
311.50 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 6 days ago
Screened 2026-10-23 · the tape above runs as of 18:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price311.50 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.30)
Last reviewed23 Oct 2026 (6 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 311.50 against the desk's fair-value range, base estimate 299.55, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.30, read 2026-10-24
Ethical does not pass the values gate
Price311.50 USD
Fair value299.55
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown325.31-4.2% to today ✓Accumulation gives way to Markdown after a 9% slide in 4 weeks
2026-09-03Read Accumulation356.19-12.5% to today Markup gives way to Accumulation after a 12% rise in 9 weeks
2026-07-02Read Markup317.97-2.0% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Krystal Biotech, Inc. holds its Markdown at $311.50. Consolidating, no directional conviction, held for 37 days.
As held on the ledger · 2026-10-23
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 37 days
Price at the screen
$311.50
Valuation
40.13 trailing · 35.38 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.50
The Workings
Five Screens, Shown in Full
Does not pass. Revenue purity
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.70%
Below 33%
Interest-bearing debt is just 0.7% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
9.60%
Below 33%
Cash held in interest-bearing accounts and securities is 9.6% of assets, under the one-third limit.
Pass
Receivables
46.76%
Below 49%
Money owed to the company is 46.8% of assets, under the 49% limit.
Pass
Revenue purity
7.24%
Below 5%
7.2% of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Krystal Biotech, clears the business-activity screen, and its debt is near-nil. Where it falls short is income purity: around 7% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when KRYS's ethical verdict changes
Today KRYS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 3.8% above the base estimate.
Third-party analyst targets: 9 covering, consensus Strong Buy. The average target sits +28% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
One approved gene fix, yet priced for perfection
Krystal Biotech sells a single gene therapy that treats a rare and painful skin disorder with one dose. The product already drives 32 percent revenue growth and a 54 percent profit margin, yet the shares sit 16 percent above our fair value at a 35 times forward earnings multiple.
We pass because the current price leaves no margin of safety. Strong analyst targets and clean ethical marks cannot offset the fact that investors are paying a premium for a company with just one commercial asset and an unknown competitive moat.
The main risk is simple: any delay in new pipeline launches or pressure on pricing would hit earnings hard at this valuation. Peak earnings and a high multiple together often signal a trap rather than an opportunity. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KRYS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markdown$311.50-2.7%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$320.25+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$320.25+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$320.25+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$320.25-0.3%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter.
2026-10-18Markdown$321.16-1.3%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter.
2026-10-02Markdown · changed$325.31-8.7%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 8.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323. Insiders have been net sellers over the past quarter.
2026-08-04Markup$366.85+15.4%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 15.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323.
2026-07-18Markup$317.97+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 34% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 126%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (9 analysts) rates it strong buy, with a mean price target of $323.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
